Complete Guide to Bioregulator Protocols — Khavinson Peptide Cycling

Bioregulator peptides — the ultra-short (2–4 amino acid) peptides developed by Vladimir Khavinson — are used differently from conventional peptides. They are not dosed continuously; instead, they follow a cyclical protocol designed to "reset" tissue-specific gene expression and then allow the body to maintain the new expression pattern between courses. This guide covers the practical framework.

The bioregulator dosing philosophy

Why cycling, not continuous use

The bioregulator hypothesis proposes that short peptides restore youthful gene expression patterns in aging tissue through epigenetic mechanisms (chromatin remodeling). Once the expression pattern is restored, it is maintained by the cell's own regulatory machinery for some period — eliminating the need for continuous dosing.

This differs fundamentally from:

• GLP-1 agonists: Require continuous use; effects reverse on discontinuation
• GH secretagogues: Effects depend on ongoing stimulation
• BPC-157: Used in finite courses because the goal (tissue healing) has an endpoint

Bioregulators are designed for periodic "maintenance courses" that refresh the epigenetic state before age-related decline resumes.

Standard course parameters

The Russian bioregulator literature consistently describes:

• Course duration: 10–20 days (most commonly 10 days)
• Frequency per year: 2–4 courses annually
• Spacing: Minimum 2–3 months between courses of the same peptide
• Dose: Typically 10 mg per day (capsule) or equivalent sublingual/injectable dose

Single-organ protocols

Brain: Pinealon (EDR)

Target: Cerebral cortex neurons

Goal: Cognitive maintenance, neuroprotection

Protocol:

• 10 mg daily for 10 days
• Repeat every 3–4 months
• Often combined with Cortagen for comprehensive CNS coverage

Expected timeline: No acute cognitive effects (unlike nootropics like Semax). Benefits are proposed to accumulate across multiple courses over months to years.

Immune system: Vilon (KE)

Target: Thymus, T-cell immunity

Goal: Immune restoration, thymic output maintenance

Protocol:

• 10 mg daily for 10–20 days
• Repeat every 3–4 months
• More frequent courses (every 2 months) during immune stress periods

Seasonal adjustment: Some practitioners recommend courses before winter (infection season) and before spring (allergy season).

Pineal gland: Epithalon (AEDG)

Target: Pineal gland, telomerase

Goal: Melatonin synthesis, telomere maintenance

Protocol:

• Injectable: 10 mg daily for 10–20 days (subcutaneous or intramuscular)
• Oral/sublingual: 10 mg daily for 20–30 days (lower bioavailability)
• Repeat every 4–6 months
• Evening dosing preferred (aligns with pineal activity)

Note: Epithalon is the most studied bioregulator and the one with the most independent (non-Khavinson) supporting data for telomerase activation.

Liver: Livagen (KEDA)

Target: Hepatocytes

Goal: Hepatoprotection, liver function maintenance

Protocol:

• 10 mg daily for 10 days
• Repeat 2–3 times per year
• Consider additional courses after hepatotoxic exposure (medications, alcohol, environmental toxins)

Vasculature: Vesilute (KED)

Target: Vascular endothelium

Goal: Endothelial function, atherosclerosis prevention

Protocol:

• 10 mg daily for 10–20 days
• Repeat 2–3 times per year
• Particularly recommended for those with cardiovascular risk factors

Cartilage: Cartalax (AED)

Target: Chondrocytes

Goal: Joint protection, cartilage maintenance

Protocol:

• 10 mg daily for 10–20 days
• Repeat 2–3 times per year
• May benefit from longer courses (20–30 days) given slow cartilage turnover

Multi-organ stacking protocols

The comprehensive approach

The full Khavinson anti-aging protocol involves simultaneous or sequential treatment of multiple organ systems. Two main stacking strategies are described:

Simultaneous stacking (all at once):

• Take multiple bioregulators concurrently during the same 10–20 day course
• Example: Epithalon + Pinealon + Vilon + Livagen all taken daily for 10 days
• Advantage: Shorter total protocol time
• Theoretical concern: Multiple epigenetic interventions simultaneously may interact unpredictably

Sequential stacking (one after another):

• Run each bioregulator as a separate 10-day course
• Example: Week 1–2 Epithalon → Week 3–4 Pinealon → Week 5–6 Vilon → Week 7–8 Livagen
• Advantage: Cleaner attribution of effects; reduced pill burden at any one time
• Disadvantage: Total protocol spans 6–8 weeks

Practitioner-recommended starter protocols

Minimal (2 organs):

• Epithalon (pineal/telomeres) + Vilon (immune)
• Run simultaneously: 10 days, every 4 months
• Rationale: Addresses the two most age-sensitive systems (telomere attrition + thymic involution)

Moderate (4 organs):

• Epithalon + Pinealon + Vilon + Livagen
• Sequential: 10 days each, total 40-day protocol, twice per year
• Rationale: Covers the key organs of aging (brain, immune, pineal, liver)

Comprehensive (6+ organs):

• All available bioregulators for each organ system
• Sequential 10-day courses or simultaneous stacking
• 2–3 complete rounds per year
• Rationale: Full-spectrum bioregulator coverage

Practical considerations

Form factors

Capsules (oral):

• Most convenient
• Lower bioavailability (GI degradation of even short peptides)
• Standard dose: 10 mg per capsule, 1–2 capsules daily
• Khavinson's group claims sufficient oral absorption for ultra-short peptides

Sublingual:

• Avoids first-pass metabolism
• Hold under tongue for 2–3 minutes before swallowing
• Potentially higher bioavailability than oral capsules
• Available as drops or dissolving tablets

Injectable:

• Highest bioavailability
• Primarily used for Epithalon (the most studied bioregulator)
• Subcutaneous or intramuscular
• Less convenient for multi-peptide protocols

Timing within the day

• Epithalon: Evening (aligns with pineal activity)
• Pinealon: Morning or midday (supports daytime cognitive function)
• Vilon: Morning (aligns with immune system circadian peak)
• Livagen: Any time (liver function is less circadian-dependent)
• With or without food: No strong data; most practitioners recommend empty stomach for sublingual, with food for capsules

What to monitor

Bioregulator effects are subtle and long-term. Objective monitoring:

• Immune function (Vilon): Lymphocyte subsets, CD4/CD8 ratio (every 6 months)
• Pineal function (Epithalon): Melatonin metabolite (6-sulfatoxymelatonin in morning urine)
• Telomere length (Epithalon): Annual measurement (expensive but directly relevant)
• Liver function (Livagen): Standard LFTs (ALT, AST, GGT)
• Cognitive function (Pinealon): Neuropsychological testing or standardized cognitive assessments

Combining with conventional peptides

Bioregulators occupy a different mechanistic space than conventional peptides and are commonly combined:

• Bioregulators + GH secretagogues: Different mechanisms (epigenetic vs. receptor stimulation)
• Bioregulators + BPC-157/TB-500: Different timeframes (chronic maintenance vs. acute healing)
• Bioregulators + GLP-1 agonists: No theoretical interaction concern
• Bioregulators + Semax/Selank: Complementary CNS approaches (epigenetic + neurotransmitter)

Evidence-based perspective

It is important to maintain intellectual honesty: bioregulator protocols are based primarily on the Khavinson research group's publications and Russian clinical experience. The following caveats apply:

1. No Phase III trials: Standard Western regulatory evidence does not exist
2. Single-source research: Most data comes from one institute
3. Mechanism debate: Whether 2–4 amino acid peptides can truly modulate gene expression remains scientifically debated
4. Safety data is reassuring: Decades of Russian use without reported adverse effects
5. Cost is low, risk appears minimal: The cost-benefit calculation may favor experimentation even with uncertain efficacy

The rational approach: implement bioregulator protocols with appropriate skepticism, track objective biomarkers, and assess personal response over multiple courses before committing to long-term use. They are not a substitute for proven interventions (exercise, nutrition, sleep, preventive medicine) but may represent a low-risk addition to a comprehensive longevity strategy.